Secondary Myeloid Malignancy after
Treatment of Acute Lymphoblastic Leukemia (ALL)
Mary V. Relling
Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, and University of Tennessee, Memphis, TN
Treatment of childhood acute lymphoblastic leukemia (ALL) has made tremendous strides over the past 20 years, but has been complicated by the induction of secondary tumors after some regimens. The cumulative incidence of therapy-related myeloid leukemia and myelodysplastic syndrome (referred to collectively as t-ML) varies widely among treatment protocols, from 1% to 12%.
[Read full article in PDF]